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Communicated by George R. Stark, Cleveland Clinic Foundation, Cleveland, OH, January 25, 2007 (received for review October 27, 2006)

Green tea polyphenol, epigallocatechin-3-gallate (EGCG) differentially regulates the cellular growth of cancer cells in a p53-dependent
manner through apoptosis and/or cell cycle arrest. In an effort to
further elucidate the mechanism of differential growth regulation by
EGCG, we have investigated the role of the tyrosine phosphatase,
SHP-2. Comparing the responses of mouse embryonic fibroblasts
(MEFs), expressing either WT or functionally inactive/truncated
SHP-2, we find that inactivation of SHP-2 remarkably sensitizes cells
to EGCG-mediated killing. MEFs lacking functional SHP-2 undergo
massive apoptosis upon treatment with EGCG. By comparing gene
expression profiles, we have identified a set of transcriptional targets
of p53 that are differentially modulated in cells undergoing apoptosis.
Western blot and real-time PCR analyses of a select group of genes
further confirm that the expression is SHP-2-dependent. Similar observations were made in MEFs lacking p53, confirming that the
expression of these ‘‘p53 target genes’’ is p53-independent. In addition, EGCG treatment induced the expression of p73 mRNA and
protein in both cell types, but not p63. Inactivation of p73 in cells
expressing nonfunctional SHP-2 markedly inhibited apoptosis and
p53 target gene expression. Although phosphorylation of JNK is
differentially regulated by SHP2, it was found to be dispensable for
EGCG-induced apoptosis and p53 target gene expression. Our results
have identified SHP-2 as a negative regulator of EGCG-inducedapoptosis and have identified a subset of p53 target genes whose
expression is paradoxically not mediated by p53 but by one of its
family members, p73.

prolyl-isomerization, recruitment into the PML-nuclear body
(PML-NB), and acetylation (reviewed in refs. 9 and 10). Moreover,
several proteins, such as Mdm2, Pin1, Notch, c-Myc, exportin-1, and
many others directly interact with p73 and either increase or
attenuate p73 transcriptional activity (reviewed in refs. 9 and 10).
In an attempt to further elucidate the pathways involved in
differential negative growth regulation by EGCG, we explored
the role of the tyrosine phosphatase SHP-2. Upon contact with
many stimuli, SHP-2 is recruited to tyrosine-phosphorylated
proteins and binds with various receptors and scaffolding adaptors (11–13). SHP-2 also regulates DNA damage-induced G2/M
cell cycle arrest, most probably via Cdc2 phosphorylation,
Cdc25C cytoplasmic translocation, and inactivation of p38 (14).
A role of SHP-2 in cell survival has also been reported (15–17).
In most receptor tyrosine kinase and cytokine signaling pathways, SHP-2 is required for full activation of the Erk/MAP
cascade and for multiple receptor-evoked functions, including
cell proliferation, differentiation, and migration (11, 12).
In this study, we find that SHP-2 protects cells from EGCGinduced apoptosis and that inactivation of SHP-2 renders the cells
sensitive to EGCG. Moreover, EGCG-induced apoptosis is accompanied by the induction of a subset of p53 target genes, seemingly
paradoxically, even in the absence of functional p53. We show that
SHP-2 negatively regulates the expression of these genes and that
the p53 family member p73 plays a critical role.

green tea 兩 MAPK pathway 兩 mouse embryonic fibroblasts 兩
transcriptional activation

SHP-2 Negatively Regulates Apoptosis Induced by EGCG. To investi-

he tumor suppressor p53 plays a key role in regulating the cell
cycle, apoptosis, genomic integrity, and DNA repair in response
to various forms of genotoxic stress, and p53 is mutated or functionally impaired in most human cancers (1, 2). From the therapeutic point of view, it is important to devise strategies to induce
apoptosis in the absence of functional p53, and a compound capable
of doing so would be a good candidate for anticancer drug
development. Earlier, we reported that green tea polyphenol,
epigallocatechin-3-gallate (EGCG) differentially regulates the cellular growth of cancer cells in a p53-dependent manner through
apoptosis and/or cell cycle arrest and established a crucial role of
p53 and its two target proteins, p21 and Bax, in EGCG-induced
apoptosis (3, 4).
In addition to p53, mammalian cells contain two closely related
proteins, p63 and p73 (5, 6). Unlike p53, p63 and p73 mutations in
human cancers are extremely rare (7). The p73 also has an
alternative promoter within intron 3, from which a truncated p73
mRNA encoding truncated versions lacking the N-terminal transactivation domain (known as ␦Np73) is transcribed. Because the
p73 protein functions as a tetramer, ␦Np73 acts as a dominantnegative suppressor of full-length p73 (8). The activity and protein
stability of p73 is regulated by a number of complex posttranslational modifications that include ubiquitination, phosphorylation,
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0700642104

gate the mechanism of differential regulation of cell growth by
EGCG, we used a pair of isogenic mouse embryonic fibroblasts
(MEFs), expressing either WT or a functionally inactive/truncated
SHP-2 (18). Because SHP-2 knockout mice die early in embryogenesis, MEFs were generated by immortalization with SV40 large
T antigen, which renders p53 inactive. The expression of WT SHP-2
was restored in cells expressing inactive/truncated SHP-2 by introducing a plasmid containing WT SHP-2. Two independent clones
were established by hygromycin selection (Fig. 1A). Cells were
treated with 120 M EGCG for 72 h. Live cells were counted by the
tryphan blue dye exclusion method, plates were photographed and
stained with methylene blue. As shown in Fig. 1B, there was a
drastic reduction in the number of live cells after EGCG treatment
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Fig. 1. SHP-2 negatively regulates EGCG-induced apoptosis. (A) Total cell lysates from cells expressing WT or truncated SHP-2 and two rescued clones (R7 and
R10) were immunoblotted with anti-SHP-2. (B) Cells were treated with 120 M EGCG for 72 h. Live cell numbers were counted by the trypan blue dye exclusion
method, and plates were photographed and stained with methylene blue. (C) Cells were treated with EGCG for 72 h. Five hundred live cells were plated for colony
formation. Results are plotted as percentages of untreated controls. (D) Cells were treated with EGCG for 72 h, fixed in ethanol, and stained with Apo-BrdU to
determine the apoptotic population. (E) Cells were treated with EGCG for 24 h, and total cell lysates were immunoblotted with an antibody that specifically
detects cleaved PARP (89 kDa) only.

in cells expressing inactive SHP-2. In contrast, there was a slight
increase in the number of live cells after EGCG treatment in cells
expressing WT SHP-2, indicating that cells continued growing for
a while but eventually arrested. Methylene blue staining also
provided similar results. We next tested the ability of the cells to
resume normal growth in a colony-forming assay. Five hundred live
cells after EGCG treatment were incubated in 15-cm plates in the
absence of EGCG, and colonies were counted 3 weeks later. As
shown in Fig. 1C, ⬇70% of the WT cells resumed normal growth,
whereas only 11% of cells expressing truncated SHP-2 formed
colonies. The rescued clones also formed more colonies (54% and
37%). These results again suggest a pivotal role of SHP-2 in
protecting cells from EGCG-induced cell death. To further investigate the mode of cell death, EGCG-treated cells were analyzed by
Annexin V–propidium iodide staining using a kit from Calbiochem
(La Jolla, CA) and the TUNEL assay using the APO-BRDU kit
from Phoenix Flow Systems, which measures apoptosis by dualcolor flow cytometry. As shown in Fig. 1D and supporting information (SI) Table 1, the great majority of cells expressing truncated
SHP-2 stained positive in the TUNEL assay and Annexin V
staining (66% and 48%, respectively). In contrast, the parental cells
and the rescue clones expressing WT SHP-2 had much reduced
TUNEL and Annexin V staining. As a molecular indicator of
apoptosis, we also measured the degradation of PARP. As shown
in Fig. 1E, PARP degradation was prevalent in cells expressing
truncated SHP-2. All of the data together thus indicate that SHP-2
protects cells from EGCG-induced apoptosis.
To further investigate whether the catalytic activity of SHP-2 is
important in protecting cells from EGCG-induced apoptosis, we
used a cell line in which the catalytic activity of WT SHP-2 is
disrupted by a dominant-negative SHP-2 (19). As shown in SI Fig.
6, the catalytic activity of SHP-2 is dispensable for its protective role
from EGCG-induced apoptosis. However, inactivation of SHP-2
led to an increase in the G2/M population.
Regulation of p53 Target Genes by EGCG in Cells Undergoing Apoptosis. In an effort to further elucidate how SHP-2 protects cells

from EGCG-induced apoptosis and affects the growth of these cells
differentially, total RNAs from both cell types were analyzed after
5420 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0700642104

EGCG treatment using gene array technology. The array results are
shown in SI Data Sets 1 and 2 and SI Fig. 7. A careful analysis of
the data revealed that the expression of a number of genes involved
in cell cycle regulation and apoptosis were differentially regulated
by SHP-2 (Fig. 2 A). Upon closer examination, we found that the
great majority of these genes are known transcriptional targets of
p53. The expression of these genes was greatly increased only in
cells expressing an inactive SHP-2. In contrast, their expression was
severely impaired in cells expressing WT SHP-2, suggesting that
SHP-2 may act as a negative regulator for their expression. As
shown in Fig. 2B, real-time PCR data completely corroborated the
microarray results. Western blot analyses of a select number of
proteins that are p53 transcriptional targets, such as Mdm2 and p21,
further confirmed that these proteins are negatively regulated by
SHP-2 (Fig. 2C). Because the response of these cells to EGCG was
in sharp contrast to their response to DNA damage (20), we treated
the cells with two DNA-damaging agents, camptothecin and cisplatin, and examined them for p21 expression. As shown in Fig. 2D,
treatment with either camptothecin or cisplatin induced the expression of p21 in SHP-2 WT cells, and this expression was greatly
impaired in cells with truncated SHP-2. Cell death was also
apparent in cells with WT SHP-2 and not in those with truncated
SHP-2 (data not shown). These experiments demonstrate that the
effects of EGCG are different and distinct from the effects of
activating the DNA-damage response pathway.
SHP-2 Negatively Regulates Apoptosis and the Expression of p53
Target Genes in the Absence of p53. As shown above, the profile of

expression of a set of genes that are p53 targets was modulated in
cells that were immortalized by SV40 large T antigen, which
inactivates p53. We next sought to unambiguously reveal whether
the role of SHP-2 in EGCG-induced cellular responses depends on
p53. For this purpose, we used an isogenic pair of cell lines (19).
p53-null MEFs expressing either WT or truncated (functionally
inactive) SHP-2 were treated with EGCG for 72 h, and the
apoptotic population was determined by TUNEL staining. As
shown in Fig. 3A, EGCG treatment led to pronounced apoptosis in
cells expressing inactive SHP-2, whereas cells carrying WT SHP-2
were resistant. We next treated these cells with EGCG for 24 h and
Amin et al.

Fig. 2. SHP-2 negatively regulates p53 target gene expression. (A) Cells were treated with 120 ⌴ EGCG for 24 h. Total RNA was used for microarray analysis
using the GE CodeLink mouse whole-genome chip containing 29,961 transcripts. Fold induction of p21, Reprimo, Cyclin G1 (CycG1), Perp, Pig11, and Wig1 are
shown compared with an untreated control. (B) Cells were treated with 120 ⌴ EGCG for 24 h. Total RNA was used in real-time PCR for the expression of p21,
Reprimo, Mdm2, Cyclin G1, Perp, Pig11, and Wig1 mRNAs. (C) Cells were treated with 120 M EGCG for the indicated times. Total cell lysates were immunoblotted
with antibodies that detect p53, p21, or Mdm2. (D) Cells were treated with camptothecin (Ct) or cisplatin (Cp) for 24 h. Total cell lysates were immunoblotted
with anti-p53 or anti-p21. UT, untreated.

Fig. 3. EGCG-induced apoptosis and p53 target gene expression in the
absence of p53. (A) Cells genetically lacking p53 but expressing either WT or
truncated SHP-2 were treated with 120 M EGCG for 72 h. Cells were fixed in
ethanol, and the apoptotic population was determined by TUNEL staining. (B)
The same cells were treated with EGCG for 24 h. Total RNA was extracted and
analyzed for the expression of p21, Reprimo, and Perp by real-time PCR.

Amin et al.

Role of p73 in Regulation of p53 Target Genes by EGCG. Because

EGCG-induced apoptosis is accompanied by the induction of a
number of p53 target genes in MEFs that were generated by
immortalization with SV40 large T antigen, which selectively inactivates p53 but not p63 or p73 (21–25), we investigated the role and
expression of these two additional members of the p53 family. Cells
expressing either WT or truncated SHP-2 were treated with EGCG
for 24 h, and total RNA was analyzed by real-time PCR. As shown
in Fig. 4A, the expression of p63 mRNA remained unchanged in
both cell types. In contrast, the expression of p73 mRNA in cells
treated with EGCG was greatly increased, apparently to a comparable level in the two cell types. We next examined the expression
of the p73 protein by Western blot analysis. Cells were treated with
EGCG, and total cell lysates were immunoblotted with anti-p73. As
shown in Fig. 4B, EGCG treatment resulted in increased expression
of p73 protein in both cell lines. These observations taken together
suggest that p73, but not p63, might be playing a role in the cellular
response to EGCG.
To further investigate whether, in the absence of p53, p73 was
responsible for the expression of p53 target genes, p53-null MEFs
expressing either WT or truncated SHP-2 were treated with EGCG
for 24 h, and total cell lysates were immunoblotted with anti-p73 or
anti-p21. As shown in Fig. 4C, EGCG induced the expression of p73
protein in both cell types in a manner similar to that found in MEFs
immortalized by SV40 large T antigen. These results suggest that,
in the absence of p53, the family member p73 may be involved in
regulating the expression of p53 targets such as p21. However, p21
protein expression was increased only in cells lacking functional
SHP-2 and not in cells with WT SHP-2. This observation again
confirmed that SHP-2 acts as a negative regulator of p53-target
gene expression by EGCG.
Oxidative stress is one of the major signals that activate many
apoptotic pathways. Although EGCG is known for its antioxidant
properties, an increasing body of evidence suggests that EGCG also
induces oxidative stress (26, 27). To identify the signal for p73
activation, we measured the generation of reactive oxygen species
(ROS) in both SHP-2 WT and mutant cells. As shown in Fig. 4D,
treatment with EGCG induced the generation of ROS in both the
cell lines. To further investigate whether ROS was the signal for p73
PNAS 兩 March 27, 2007 兩 vol. 104 兩 no. 13 兩 5421
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analyzed total RNA for the expression of p21, Reprimo, and Perp by
real-time PCR. As shown in Fig. 3B, EGCG treatment induced the
expression of p21, Reprimo, and Perp in cells with inactive SHP-2.
In contrast, the expression of these genes was significantly suppressed in cells expressing WT SHP-2. These results further confirmed a negative regulatory role of SHP-2 in p53 target gene
expression in the absence of p53. Because both of these cells were
genetically p53-deficient, apoptosis and expression of p53 target
gene are likely to be mediated by p53-independent signaling.

Fig. 4. Oxidative stress induced induction of p73 but not p63 by EGCG. (A)
Cells were treated with EGCG for 24 h. Total RNA was analyzed for the
expression of p73 and p63 by real-time PCR. (B) Cells were treated with EGCG
for the indicated times. Total cell lysates were analyzed by Western blotting
and probed with anti-p73. (C) Cells genetically lacking p53 but expressing
either a WT or truncated SHP-2 were treated with EGCG for 24 h. Total cell
lysates were immunoblotted with anti-p73 or anti-p21. (D) Cells were treated
with EGCG for 24 h, and intracellular ROS generation was measured by HE
staining. (E and F) SHP-2 mutant cells were treated with EGCG alone, EGCG
plus 5 mM Tiron, or 5 mM Tiron alone for 24 h. Tiron was added 2 h before the
addition of EGCG. ROS was measured by HE staining, and whole cell lysates
were immunoblotted with anti-p73. UT, untreated.

induction, SHP-2 mutant cells were treated with a known antioxidant, Tiron. As shown in Fig. 4 E and F, pretreatment with Tiron
inhibits the generation of ROS and also substantially inhibits
EGCG-induced p73 induction. However, there is a small increase
in p73 protein by Tiron itself, suggesting a ROS-independent
regulation pf p73 induction. All these data suggest that EGCG
treatment induces oxidative stress, which may activate p73.

Fig. 5. p73-dependent expression of p53 target genes and apoptosis in
response to EGCG. (A) Cells expressing inactive SHP-2 (M3) were transfected
with a T7-tagged dominant-negative p73 plasmid, and two clones (C18 and
C22) were established. (Upper) Total cell lysates were probed with anti-T7.
(Lower) Cells were treated with EGCG for 24 h, and total cell lysates were
analyzed by the Western blot method, using anti-Mdm2. (B) Cells were treated
with EGCG for 72 h, and the apoptotic population was measured by TUNEL
staining. (C) Cells were treated with EGCG for 24 h, and total RNA was
analyzed by real-time PCR for expression of the corresponding genes.

Downloaded at MARSHALL UNIVERSITY Libraries on March 24, 2020

Inactivation of p73 Reverses Apoptosis and Expression of p53 Target
Genes. As described above, the treatment of EGCG results in

comparable levels of p73 mRNA and protein induction in both
SHP-2 WT and mutant cells. Because p73 activity is known to be
modulated by a number of complex posttranslational events such as
ubiquitination, phosphorylation, isomerization, acetylation, and
interaction with several other proteins, we sought to further explore
whether p73 is necessary for the regulation of p53 target genes and
apoptosis by EGCG. p73 activity was disrupted by overexpressing
dominant-negative p73 (DDp73) in cells expressing truncated
SHP-2. The DDp73 mutant is tagged with a T7-epitope and has
been shown to inactivate the activity of p73 (28). Two independent
clones (C18 and C22) expressing DDp73 as determined with T7
antibody were established by G418 selection (Fig. 5A). Expression
of Mdm2, a known target of p53, previously found to be induced by
EGCG (Fig. 2) was also examined in these clones after EGCG
treatment (Fig. 5A Lower). The EGCG-induced expression of
Mdm2 is suppressed in these clones. The clones were treated with
EGCG along with parental cells, and the apoptotic population was
determined by TUNEL staining. As shown in Fig. 5B, inactivation
of p73 substantially inhibits apoptosis in both the clones. We next
treated these cells with EGCG for 24 h and analyzed total RNA for
the expression of p21, Reprimo, Cyclin G1, Perp, Wig1, and Pig11. As
shown in Fig. 5C, the expression of all of these genes was markedly
inhibited after p73 inactivation. These observations together establish that, in the absence of functional p53, its family member p73
indeed regulates the expression of p53 target genes and apoptosis.
5422 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0700642104

JNK Activation Is Dispensable for Apoptosis and p53 Target Gene
Expression. As mentioned earlier, SHP-2 is important for the

regulation of p38 and JNK and is required for full activation of
the Erk/MAP kinase pathway (11, 12). To further investigate the
mechanism of differential role of SHP-2 in cellular growth regulation by EGCG, we examined the activation of JNK, Erk, p38, and
Akt. As shown in SI Fig. 8A, EGCG treatment induced the
phosphorylation of JNK in cells with truncated SHP-2, which was
severely impaired in cells expressing WT SHP-2. In contrast, a
transient phosphorylation of Erk was observed after 10 min in
SHP-2 WT cells but not in SHP-2 mutant cells. Phosphorylation of
Akt was markedly increased upon treatment with EGCG, and the
level of induction was comparable between the two cell lines.
However, there was no phosphorylation of p38 after EGCG
treatment (data not shown). These results suggest that SHP-2 acts
as a negative regulator for EGCG-induced JNK activation but as a
positive regulator for Erk activation. These results also correlated
with the known roles of these proteins in apoptosis. Because JNK
activation regulates stress-induced apoptosis, its downstream target
c-Jun is important for p73 activation (29), and a recent report
suggests the involvement of JNK in EGCG-induced apoptosis (26),
we next focused on JNK activation. To further confirm that SHP-2
negatively regulates EGCG-induced JNK phosphorylation, we analyzed JNK activation in the rescued clones. As shown in SI Fig. 8B,
EGCG-induced JNK phosphorylation was suppressed after reinAmin et al.

No Direct Interaction of SHP2 with Tyrosine Phosphorylated Proteins
or p73. It is well established that SHP-2 becomes activated by

Downloaded at MARSHALL UNIVERSITY Libraries on March 24, 2020

binding of its SH2 domain to a phosphotyrosine residue of a target
protein (11, 12). To investigate whether treatment with EGCG
generates any tyrosine phosphorylated protein, total cell lysates
from both the cell types were immunoblotted with an antiphosphotyrosine antibody. As shown in SI Fig. 9A, EGCG-treatment did
not induce tyrosine phosphorylation of any cellular protein. Furthermore, SHP-2 immunoprecipitates from whole-cell lysates prepared with a buffer that does not interfere with complex formation
(30) were immunoblotted with antiphosphotyrosine antibody to
detect whether SHP-2 binds to any tyrosine phosphorylated protein. As shown in SI Fig. 9B, no additional bands were detected, thus
suggesting that SHP-2 is not phosphorylated by EGCG nor does it
interact with any tyrosine phosphorylated protein. We also investigated whether SHP-2 physically binds to p73. SHP-2 immunoprecipitates were immunoblotted with anti-p73. Again, as shown in SI
Fig. 9C, no binding was detected.
Discussion
p53 plays a central role in the apoptotic response to chemotherapeutic agents. It was reported previously that EGCG had remarkable chemopreventive and chemotherapeutic properties, due
mainly to its ability to induce apoptosis (3, 4, 31–33). In this study,
we found that the protein tyrosine phosphatase SHP-2 serves as a
negative regulator for EGCG-induced apoptosis because its inactivation renders cells sensitive to EGCG. However, the catalytic
activity of SHP-2 is not important in mediating its protective role.
SHP-2 is known to be involved in multiple signaling pathways that
regulate cellular growth, survival, differentiation, apoptosis, and
migration (11–14, 19, 20, 34). The roles of SHP-2 in mediating
cellular growth and survival by activating Ras-MAPK and Akt
signaling, thereby protecting cells from apoptosis, are well studied.
In contrast, some studies suggest that SHP-2 is involved in mediating apoptosis in response to DNA damage or deprivation of
growth factors (19, 20). However, the downstream targets of SHP-2
in mediating cell survival or apoptosis are not well characterized.
Although earlier studies have identified SHP-2 as a positive regulator of apoptosis in response to DNA damage, our current
observations suggest a completely opposite role of SHP-2 as a
negative regulator of apoptosis in response to a well known
chemopreventive agent in the very same cells. This intriguing
observation further validates the notion that a single protein can
influence signaling in diverse ways and thus influence the biological
outcome.
Our observations establish that SHP-2 negatively regulates the
expression of a subset of genes that are involved in cell cycle arrest
and apoptosis and that have been well characterized as bona fide
transcriptional targets of p53. Furthermore, the current findings
also demonstrate that the expression of these genes is mediated in
a p53-independent but p73-dependent manner because the MEFs
used in the present study were either genetically p53-deficient or
immortalized by SV40 large T antigen, which inactivates p53.
Amin et al.

Although some of these genes had been reported to be induced by
p73, many were not. Our current observations also indicate that
SHP-2 confers a protective function, probably by disabling p73
activity, thus inhibiting the expression of these genes.
Unlike p53, p73 and p63 are frequently functional and even
overexpressed in some tumors (35). Therefore, these transcription
factors are now considered to be an important determinant of
cellular sensitivity to anticancer drugs, particularly in tumors lacking functional p53. In a search for the mechanism of apoptosis in
the absence of p53, we found that EGCG treatment induced the
expression of p73 but not p63 and that inactivation of p73 protects
cells from EGCG-induced apoptosis. The results of our study are
consistent with previous reports that p73 is sufficient to induce
apoptosis in cells lacking functional p53 (36–38). However, there is
no notable difference in the expression levels of p73 between SHP-2
WT and mutant cells, although there are remarkable differences in
apoptosis and expression of target genes. We also did not find any
differential distribution of p73 in the nuclear and cytosolic fractions
or activation of p38, a kinase that activates p73 (data not shown).
In addition to its subcellular localization, and explained earlier in
the introduction section, the activity of p73 is modulated by a
number of complex posttranslational events that include ubiquitination, sequential phosphorylation, prolyl-isomerization, recruitment into the PML-nuclear body (PML-NB), acetylation, and
interaction with a large number of proteins. We believe that SHP-2
modulates one or more of these events to modulate p73 function.
Obviously, a systematic study to identify as how SHP-2 regulates
p73 activity is warranted.
The downstream targets required for p53 and its family members
to execute apoptosis are many and vary with the cell type and
stimulus. The BH3-only protein Bax, PUMA, and NOXA play
important roles in mitochondrial apoptotic pathways induced in
p53-dependent and -independent manners (3, 39–41). Perp, Pig11,
and Wig1 are also involved in apoptosis (42–44). Another important p53 target p21 is well known for protecting cells in response to
a variety of signals by halting the cell cycle at both the G1 and G2/M
checkpoints (1, 2). We have also previously reported that both p21
and Bax play an important role in p53-dependent apoptosis induced
by EGCG (3, 4). Although the roles of these p53 targets in apoptosis
have been well studied, it is not yet clear which factors regulate their
induction or lead to the expression of which targets. We found that
treatment of cells with EGCG induced a number of these genes,
including Cyclin G1, Perp, Wig1, and Pig11. A more in-depth study
by ablating the expression of one protein at a time is needed to
establish their role in apoptosis.
In conclusion, our study identifies SHP-2 as a protective factor of
cells lacking functional p53 from EGCG-induced apoptosis and
reveals a number of targets for EGCG-induced apoptosis that are
expressed in the absence of functional p53 and that have not
previously been reported to be so induced. Moreover, this report
identifies a crucial role for p73 in EGCG-induced apoptosis and
identifies a number of previously unidentified p73 target genes.
Therefore, our study will hopefully open an avenue for apoptosis
research, particularly in cells lacking functional p53, and will lead to
the development of new anticancer drugs. A detailed mechanistic
study is warranted to understand the negative regulatory role of
SHP-2 in apoptosis and p53 target gene expression.
Materials and Methods
Cell Culture, Plasmid Transfection, and Cell Treatment. All cells were

maintained in DMEM containing 10% FBS. WT SHP-2 plasmid in
pCDNA3-Hygro vector has been described earlier (18). Dominantnegative p73 (amino acids 327–636) plasmid was obtained from
David Boothman (University of Texas Southwestern, Dallas, TX).
Generation and validation of the plasmid is described elsewhere
(28). SHP-2 mutant cells were transfected with these plasmids by
using the Lipofectamine Plus reagent according to the supplier’s
instructions. Individual clones were selected by using hygromycin
PNAS 兩 March 27, 2007 兩 vol. 104 兩 no. 13 兩 5423
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troduction of SHP-2. These results again suggest that SHP-2 is a
negative regulator of EGCG-induced JNK phosphorylation. To test
the importance of JNK activation in EGCG-induced p53 target
gene expression, cells expressing truncated SHP-2 were pretreated
with the specific JNK inhibitor, SP600125, for 1 h, followed by
EGCG treatment for 24 h. Total RNA was analyzed for the
expression of p21, Reprimo, Cyclin G1, Perp, Pig11, and Wig1 by
real-time PCR. As shown in SI Fig. 8C, pretreatment with SP600125
had no significant effect on the expression of these genes. To further
confirm that JNK activation is dispensable for EGCG-induced
apoptosis, cells expressing truncated SHP-2 were pretreated with
SP600125, followed by EGCG treatment for 72 h. As shown in SI
Fig. 8D, inhibition of JNK activation had no significant effect on cell
growth or apoptosis induced by EGCG.

and G418. For EGCG treatment, 4 ⫻ 105 cells were plated in 10-cm
culture dishes. After overnight incubation, the media were replaced, and the cells were treated with 120 M EGCG for 72 h, if
not indicated otherwise.
Materials and Chemicals. EGCG was obtained from Tokyo Food
Techno (Tokyo, Japan). The specific JNK inhibitor SP600125
was purchased from Calbiochem. Antibodies that recognize
p42/44, p38 MAPK, JNK, Akt, SHP-2, Cleaved PARP, and Akt
were from Cell Signaling Technology (Danvers, MA); Erk2, Bax,
p21, p53, and SHP-2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); T7-Tag antibody was from Novagen
(San Diego, CA); and p73 antibody was from Bethyl Laboratories (Montgomery, TX).
TUNEL Assay. After treatment with 120 M EGCG for 72 h, cells
were fixed in 70% ethanol and labeled with fluorescein-tagged
bromodeoxy-uridine triphosphate (Brd-UTP) and propidium iodide as in the manufacturer’s protocol, by using the APO-BRDU
apoptosis kit (Phoenix Flow Systems, San Diego, CA).
Annexin V Staining. Annexin V staining was performed by using a

kit from Calbiochem according to the supplier’s instruction. Briefly,
after treatment with EGCG, cells were stained with Annexin
V-FITC, followed by propidium iodide and were analyzed immediately by flow cytometry.
RNA Isolation and Microarray Analysis. Total RNA was extracted
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from the cells by using the Qiagen RNeasy mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. Biotinlabeled cRNA was prepared by linear amplification of the Poly
(A)⫹ RNA population within the total RNA sample. Purified
cRNA was fragmented to uniform size and applied to CodeLink
Bioarrays (GE Healthcare, Piscataway, NJ) in hybridization buffer.
After hybridization, arrays were washed and stained with Cy5Streptavidin dye conjugate. Dried arrays were scanned with a
GenePix 4000B scanner. Arrays were processed with CodeLink
Expression Analysis software (GE Healthcare), and data were
analyzed with GeneSpring software (Silicon Genetics, Redwood
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City, CA). To compare individual expression values across arrays,
raw intensity data (generated from CodeLink Expression 2 software) from each gene was normalized to the median intensity of the
array. Only genes which have values greater than background
intensity in at least one condition were used for further analysis. The
arrays used in our experiment were GE CodeLink mouse wholegenome arrays. Information on these arrays can be seen at
www5.amershambiosciences.com/aptrix/upp01077.nsf/Content/
codelink㛭uni.
Measurement of ROS. Intracellular ROS generation was measured

by flow cytometry following staining with hydroethidium (HE),
which is oxidized to ethidium bromide. Briefly, after treatment with
EGCG for 24 h, cells were stained with HE and analyzed by using
an Epics XL Flow Cytometer (Coulter, Miami, FL).
Real-Time PCR. Total RNA extracted as above was used for real-time
PCR. Amplification of the corresponding genes was done by using
primer sets supplied by Applied Biosystems (Foster City, CA). The
data were analyzed for fold induction of each gene as compared
with the untreated sample.
Western Blot Analyses. Total cellular proteins were isolated by lysing
the cells in 20 mM Tris䡠HCl, pH 7.5, 2% (wt/vol) SDS, 2 mM
benzamidine, and 0.2 mM phenylmethanesulfonyl fluoride. Protein
concentrations were determined by the Bradford method (BioRad, Hercules, CA). Proteins were resolved on SDS-10% polyacrylamide gels and then transferred to polyvinylidene diflouride
(PVDF) membranes. The membranes were blocked in 5% nonfat
skimmed milk and incubated with the antibody, followed by incubation with a secondary antibody. Proteins were visualized by using
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences,
Boston, MA) as directed by the manufacturer.
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